{"nctId":"NCT00623636","briefTitle":"Phase 3 Study of MAP0004 in Adult Migraineurs","startDateStruct":{"date":"2008-07"},"conditions":["Migraine Disorders"],"count":902,"armGroups":[{"label":"MAP0004","type":"EXPERIMENTAL","interventionNames":["Drug: MAP0004"]},{"label":"Placebo","type":"OTHER","interventionNames":["Drug: MAP0004","Drug: Placebo"]}],"interventions":[{"name":"MAP0004","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Major Inclusion Criteria:\n\n* Male or female between 18 and 65 years of age.\n* History of episodic, acute migraine (with or without aura) with onset prior to 50\n\nMajor Exclusion Criteria:\n\n* Known allergy or sensitivity or contraindication to study drugs or their formulations\n* History of chronic pulmonary disease, coronary artery disease (CAD), liver disease, kidney disease, seizures, stroke, or major psychiatric condition.\n* Any condition that, in the opinion of the Investigator, would make the subject unsuitable for study participation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Pain Relief at 2 Hours From Time of First Dose","description":"Pain relief at 2 hours was defined as change in rating from severe or moderate (score 3 or 2) to a rating of none or mild (score 0 or 1) at the 2-hour time point and no usage of rescue medications from the time of first dose to 2 hours.\n\nThe 4-point scale from the International Headache Society was used:\n\n0 = none; 1 = mild symptom, not interfering with normal daily activities; 2 = moderate symptom, causing some restriction to normal activities; 3 = severe, leading to inability to perform daily activities","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"136","spread":null},{"groupId":"OG001","value":"231","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Photophobia Free at 2 Hours From Time of First Dose","description":"Photophobia free at 2 hours was defined as a rating of none (score 0) at the 2-hour time point and no usage of rescue medications from the time of first dose to 2 hours.\n\nThe 4-point scale from the International Headache Society was used:\n\n0 = none; 1 = mild symptom, not interfering with normal daily activities; 2 = moderate symptom, causing some restriction to normal activities; 3 = severe, leading to inability to perform daily activities","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"182","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Phonophobia Free at 2 Hours From Time of First Dose","description":"Phonophobia free at 2 hours was defined as a rating of none (score 0) at the 2-hour time point and no usage of rescue medications from the time of first dose to 2 hours.\n\nThe 4-point scale from the International Headache Society was used:\n\n0 = none; 1 = mild symptom, not interfering with normal daily activities; 2 = moderate symptom, causing some restriction to normal activities; 3 = severe, leading to inability to perform daily activities","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"208","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Nausea Free at 2 Hours From Time of First Dose","description":"Nausea free was defined as a rating of none (score 0) at the 2-hour time point and no usage of rescue medications from the time of first dose to 2 hours post-dose.\n\nThe 4-point scale from the International Headache Society was used:\n\n0 = none; 1 = mild symptom, not interfering with normal daily activities; 2 = moderate symptom, causing some restriction to normal activities; 3 = severe, leading to inability to perform daily activities","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"234","spread":null},{"groupId":"OG001","value":"266","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Sustained Pain Relief From 2 to 24 Hours","description":"Sustained Pain Relief was defined as a rating of none or mild (score 0 or 1) at the 2-hour time point that was maintained during the 2-24 hour post-dose period and no use of rescue medication from the time of first dose to 24 hours.\n\nThe 4-point scale from the International Headache Society was used:\n\n0 = none; 1 = mild symptom, not interfering with normal daily activities; 2 = moderate symptom, causing some restriction to normal activities; 3 = severe, leading to inability to perform daily activities","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"166","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Whose Time to Pain Relief Occurred Within 2 Hours","description":"The number of subjects who reported pain relief (score of 0 or 1) at any time within the 2 hours following the time of first dose and who did not use rescue medication on or prior to this point. Subjects who did not reach pain relief by the end of the time period were not included.\n\nThe 4-point scale from the International Headache Society was used: 0 = none; 1 = mild symptom, not interfering with normal daily activities; 2 = moderate symptom, causing some restriction to normal activities; 3 = severe, leading to inability to perform daily activities","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"156","spread":null},{"groupId":"OG001","value":"244","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Pain Relief at 4 Hours","description":"Pain Relief at 4 hours was defined as a change in rating from severe or moderate (score 3 or 2) to none or mild (score 0 or 1) at the 4-hour time point and no use of rescue medication from the time of first dose to 4 hours.\n\nThe 4-point scale from the International Headache Society was used:\n\n0 = none; 1 = mild symptom, not interfering with normal daily activities; 2 = moderate symptom, causing some restriction to normal activities; 3 = severe, leading to inability to perform daily activities","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"145","spread":null},{"groupId":"OG001","value":"254","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Pain Relief at 10 Minutes","description":"Pain Relief at 10 minutes was defined as a change in rating from severe or moderate (score 3 or 2) to none or mild (score 0 or 1) at the 10 minute time point and no use of rescue medication from the time of first dose to 2 hours.\n\nThe 4-point scale from the International Headache Society was used:\n\n0 = none; 1 = mild symptom, not interfering with normal daily activities; 2 = moderate symptom, causing some restriction to normal activities; 3 = severe, leading to inability to perform daily activities","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":404},"commonTop":["Upper Respiratory Tract Infection","Nausea","Nasopharyngitis","Pharmaceutical Product Compaint","Sinusitis"]}}}